An Oral Ketamine Drug for Depression — Minus the Trip?
Recent clinical trials indicate that a new oral formulation of ketamine, known as KET01, may offer antidepressant benefits without the dissociative side effects often associated with traditional ketamine treatments. In a phase 1 study, researchers compared KET01 to intranasal esketamine. While esketamine users experienced significant dissociation, those who received KET01 reported minimal symptoms. These findings suggest that the antidepressant mechanism of ketamine might operate independently of the hallucinogenic or trippy experiences that usually accompany its use.
A phase 2 trial further evaluated the safety and efficacy of KET01 in patients diagnosed with treatment-resistant depression. Participants took the drug daily alongside their standard antidepressant therapy over a three-week period. Data showed that individuals receiving KET01 experienced notable reductions in depressive symptoms early in the treatment window, specifically at days 4 and 7. However, the study did not meet its primary clinical efficacy endpoint at day 21, as the statistical difference between the active drug and the placebo group narrowed.
The research, published in JAMA Network Open, highlights a key challenge in this field of medicine. Functional unblinding occurs when participants identify whether they have received a psychoactive drug based on their physical sensations, which complicates efforts to measure actual antidepressant outcomes. Because KET01 produces fewer dissociative effects and avoids the cardiovascular fluctuations common with other formulations, investigators believe it could serve as a safer alternative for patients who have cardiovascular risks.
Experts noted that while the drug shows promise, current evidence is not yet sufficient to support broad use. Some researchers suggest that oral doses may not reach the plasma concentrations required to sustain long-term antidepressant effects. Future research will need to address these dosing limitations and determine if the drug's metabolites are the primary drivers of its clinical activity. For now, the study provides data supporting the idea that a non-dissociative pathway to treating depression is medically plausible.